CGON · CG Oncology, Inc.
$77.61
-3.07 (-3.81%)
At close · Aug 20
Market Cap
$7.05B
Shares
88.64M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$77.61
Open$79.50
Day$77.17–79.71
52W close$25.42–80.68
Avg vol 30d863K
Short int11.8M · 13.4% float · 13.5d
Short vol58%
DataJan 2024–Aug 2026
Filing10-Q · Aug 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+31%
above
Price vs 50-day avg
+10%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
94%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+9%
trailing
6-month return
+32%
trailing
YTD return
+87%
this year
Relative strength
+21%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $71 › 200d $59 — 50d above 200d
Institutional flow
Distributing
-2% holders QoQ · +36 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
13.36% of float · ▼ -2.2% MoM · 13.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
234 holders — near 2-yr high, broad support
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
+255%
Y/Y
EPS growth
−48%
Y/Y
Free cash flow
$-132.5M
Balance sheet
$29.5M
net cash
Quant / Vol
risk profile
Volatility
58%
annualized · 1-yr
Max drawdown
−27%
past year
ATR
4.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+31%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
94%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $71 › 200d $59 — 50d above 200d
Institutional flow
Distributing
-2% holders QoQ · +36 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
13.36% of float · ▼ -2.2% MoM · 13.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
234 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $25
Now $78 · 94%
Range high $81
vs 200-day avg +31%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CGON
this stock
CG Oncology, Inc.
|
$7.05B | +86.9% | +254.7% | — | 13.4% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CGON | +3.9% | +9.1% | +32.0% | +9.0% | +86.9% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +5.8% | +5.8% | +20.8% | +6.9% | +75.1% |
Key facts
CIK
1991792
CUSIP
156944100
13F (30d)
230 filings
224 filers
Visit website
Investor relations